Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases (Q37406393)

20 August 2017

1 reference

title

Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases (English)

1 reference

20 August 2017

1 reference

1 reference

4

Jean-Nicolas Vauthey

0 references

author name string

Yun Shin Chun

series ordinal

1

1 reference

PubMed ID

19261256

20 August 2017

Alexis Laurent

series ordinal

2

1 reference

PubMed ID

19261256

20 August 2017

Dipen Maru

series ordinal

3

1 reference

20 August 2017

1 March 2009

1 reference

Lancet Oncology Commission

20 August 2017

1 reference

20 August 2017

10

1 reference

20 August 2017

3

1 reference

20 August 2017

278-286

1 reference

Major hepatic resections for metastatic colorectal cancer

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Perioperative chemotherapy for resectable hepatic metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Mitochondria in steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Irinotecan pharmacogenetics: is it time to intervene?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

The effect of cisplatin and transplatin on the conformation and association of F-actin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Impact of steatosis on perioperative outcome following hepatic resection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Steatosis as a risk factor in liver surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Flare-up of nonalcoholic steatohepatitis after hepatectomy resulted in hepatic failure in a patient with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Comparison of CT methods for determining the fat content of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Preoperative radiographic assessment of hepatic steatosis with histologic correlation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Magnetic resonance imaging and spectroscopy for monitoring liver steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Laparoscopic findings in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Diagnosis and therapy of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Safe liver resection following chemotherapy for colorectal metastases is a matter of timing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Body surface area and body weight predict total liver volume in Western adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Extending the frontiers of resectability in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Glutamine preserves liver glutathione after lethal hepatic injury

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Parenteral glutamine protects hepatic function during bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Prevention and treatment of veno-occlusive disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

Effect of molecular therapeutics on liver regeneration in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970064-6

7 January 2021

10.1016/S1470-2045(09)70064-6

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19261256